[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20200179A - Sales de inhibidores de tam - Google Patents

Sales de inhibidores de tam

Info

Publication number
CR20200179A
CR20200179A CR20200179A CR20200179A CR20200179A CR 20200179 A CR20200179 A CR 20200179A CR 20200179 A CR20200179 A CR 20200179A CR 20200179 A CR20200179 A CR 20200179A CR 20200179 A CR20200179 A CR 20200179A
Authority
CR
Costa Rica
Prior art keywords
salts
derivatives useful
pyrrolotriazine derivatives
phenyl
inhibitors
Prior art date
Application number
CR20200179A
Other languages
English (en)
Inventor
Yongzhong Wu
Yongchun Pan
Qun Li
Jiacheng Zhou
Zhongjiang Jia
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR20200179A publication Critical patent/CR20200179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud proporciona formas de sal de N-(4-(4-Amino-7-(1-isobutirilpiperidin-4-il)pirrolo[1,2-f][1,2,4]triazin-5-il)fenil)-1-isopropil-2,4-dioxo-3-(piridin-2-il)-1,2,3,4-tetrahidropirimidina-5-carboxamida y N-(4-(4-Amino-7-(1-isobutirilpiperidin-4-il)pirrolo[1,2-f][1,2,4]triazin-5-il)fenil)-1-isopropil-2,4-dioxo-3-fenil-1,2,3,4-tetrahidropirimidina-5-carboxamida, que son útiles como inhibidores de cinasas TAM, así como procesos e intermedios relacionados con estas.
CR20200179A 2017-09-27 2018-09-26 Sales de inhibidores de tam CR20200179A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564070P 2017-09-27 2017-09-27
US201862714196P 2018-08-03 2018-08-03
PCT/US2018/052925 WO2019067594A1 (en) 2017-09-27 2018-09-26 SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS

Publications (1)

Publication Number Publication Date
CR20200179A true CR20200179A (es) 2020-11-02

Family

ID=63794769

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200179A CR20200179A (es) 2017-09-27 2018-09-26 Sales de inhibidores de tam

Country Status (33)

Country Link
US (3) US10633387B2 (es)
EP (2) EP3988552A1 (es)
JP (2) JP7504791B2 (es)
KR (1) KR20200088308A (es)
CN (1) CN111386273B (es)
AU (2) AU2018342471B2 (es)
BR (1) BR112020006145A2 (es)
CA (1) CA3077308A1 (es)
CL (2) CL2020000791A1 (es)
CO (1) CO2020005009A2 (es)
CR (1) CR20200179A (es)
CY (1) CY1124952T1 (es)
DK (1) DK3687996T3 (es)
EC (1) ECSP20021655A (es)
ES (1) ES2904458T3 (es)
GE (1) GEP20227429B (es)
HU (1) HUE057190T2 (es)
IL (1) IL273579A (es)
JO (1) JOP20200081A1 (es)
LT (1) LT3687996T (es)
MA (1) MA50655B1 (es)
MD (1) MD3687996T2 (es)
MX (1) MX2020003375A (es)
PE (1) PE20210002A1 (es)
PH (1) PH12020550143A1 (es)
PL (1) PL3687996T3 (es)
PT (1) PT3687996T (es)
RS (1) RS62872B1 (es)
SA (1) SA520411638B1 (es)
SG (1) SG11202002821UA (es)
SI (1) SI3687996T1 (es)
TW (1) TWI821200B (es)
WO (1) WO2019067594A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
UA123785C2 (uk) 2016-03-28 2021-06-02 Інсайт Корпорейшн Сполуки піролотриазину як інгібітори tam
JP7332472B2 (ja) 2016-12-22 2023-08-23 ノバルティス アーゲー Ｎｍｄａ受容体モジュレーターおよびその使用
CR20200179A (es) 2017-09-27 2020-11-02 Incyte Corp Sales de inhibidores de tam
SG11202013163TA (en) 2018-06-29 2021-01-28 Incyte Corp Formulations of an axl/mer inhibitor
SG11202101125VA (en) 2018-08-03 2021-03-30 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
TW202140027A (zh) 2020-03-06 2021-11-01 美商英塞特公司 包含ａｘｌ／ｍｅｒ及ｐｄ—１／ｐｄ／ｌ１抑制劑之組合療法
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
JPWO2023286719A1 (es) * 2021-07-13 2023-01-19

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148719A0 (en) 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Kinase inhibitors as therapeutic agents
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
WO2005025515A2 (en) 2003-09-12 2005-03-24 California Institute Of Technology Proteasome pathway inhibitors and related methods
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
DK1951724T3 (da) 2005-11-17 2011-08-15 Osi Pharmaceuticals Llc Sammensmeltede bicykliske mTOR-inhibitorer
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX346183B (es) 2005-12-13 2017-03-10 Incyte Holdings Corp Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas heteroarilo-sustituidas como inhibidores de cinasas janus.
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
WO2007120752A2 (en) 2006-04-12 2007-10-25 Vertex Pharmaceuticals Incorporated 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
JP5406725B2 (ja) 2006-12-14 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な化合物
EP2078010B1 (en) 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
US9650391B2 (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals Inc. N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
US7872000B2 (en) 2006-12-29 2011-01-18 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
NZ583061A (en) 2007-08-15 2012-06-29 Vertex Pharma 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2215085B1 (en) 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
CA2704052C (en) 2007-10-26 2015-04-21 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
ES2391373T3 (es) 2008-04-16 2012-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Derivados de quinoleína como inhibidores de la cinasa AXL
CA2728729C (en) 2008-06-23 2016-09-27 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
SI2328888T1 (sl) 2008-07-09 2013-03-29 Rigel Pharmaceuticals, Inc. Premoščeni biciklični heteroaril substituirani triazoli, uporabni kot inhibitorji Axl
EP2326641B1 (en) 2008-07-09 2014-09-03 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
US20100075973A1 (en) 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
AU2010210986A1 (en) 2009-02-09 2011-08-25 Supergen, Inc. Pyrrolopyrimidinyl Axl kinase inhibitors
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
BR112012006639A2 (pt) 2009-09-25 2015-09-08 Vertex Pharma métodos para preparar derivados de pirimidina úteis como inibidores de protéina quinase
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
JP5752232B2 (ja) 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
CA2761074A1 (en) 2010-05-05 2011-11-10 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US20120115848A1 (en) 2010-10-08 2012-05-10 Elan Pharmaceuticals, Inc. Inhibitors of Polo-Like Kinase
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9133162B2 (en) 2011-02-28 2015-09-15 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
MX2013010871A (es) 2011-03-23 2014-01-31 Amgen Inc Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
WO2012135800A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DK2751109T3 (en) 2011-09-02 2017-01-23 Incyte Holdings Corp HETEROCYCLYLAMINES AS PI3K INHIBITORS
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
RU2631655C2 (ru) 2011-10-03 2017-09-26 Зэ Юниверсити Оф Норд Каролина Эт Чапель Хилл Пирролопиримидиновые соединения для лечения злокачественной опухоли
PL2780338T3 (pl) 2011-11-14 2017-04-28 Ignyta, Inc. Pochodne uracylu jako inhibitory kinaz AXL i c-MET
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
AU2013216006B2 (en) 2012-01-31 2017-06-08 Daiichi Sankyo Company, Limited Pyridone derivatives
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
ES2889757T3 (es) 2012-09-06 2022-01-13 Plexxikon Inc Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
EP2922857B1 (en) 2012-11-20 2018-01-03 ProQinase GmbH Thioether derivatives as protein kinase inhibitors
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US9012466B2 (en) 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
JP6493218B2 (ja) 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
SG11201605417QA (en) 2014-02-03 2016-08-30 Cadila Healthcare Ltd Heterocyclic compounds
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
WO2016183071A1 (en) * 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
WO2017062797A1 (en) 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill The methods for treatment of tumors
MX2018004516A (es) 2015-10-13 2018-08-01 Nihon Nohyaku Co Ltd Compuesto heterociclico condensado con contenido de grupo oxima o su sal, insecticida agricola y horticola que comprende el compuesto y metodo para usar el insecticida.
JP6921818B2 (ja) 2015-11-14 2021-08-18 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
US9695150B2 (en) 2015-11-14 2017-07-04 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
UA123785C2 (uk) 2016-03-28 2021-06-02 Інсайт Корпорейшн Сполуки піролотриазину як інгібітори tam
AU2017252328B2 (en) 2016-04-22 2023-02-23 Incyte Corporation Formulations of an LSD1 inhibitor
AR108875A1 (es) * 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
SG11201900238UA (en) 2016-07-15 2019-02-27 Ionis Pharmaceuticals Inc Compounds and methods for modulation of smn2
CR20200179A (es) 2017-09-27 2020-11-02 Incyte Corp Sales de inhibidores de tam
SG11202013163TA (en) 2018-06-29 2021-01-28 Incyte Corp Formulations of an axl/mer inhibitor

Also Published As

Publication number Publication date
WO2019067594A1 (en) 2019-04-04
JP7504791B2 (ja) 2024-06-24
RS62872B1 (sr) 2022-02-28
CN111386273B (zh) 2024-06-14
DK3687996T3 (da) 2022-01-10
US20190112313A1 (en) 2019-04-18
TWI821200B (zh) 2023-11-11
ES2904458T3 (es) 2022-04-05
US20220227770A1 (en) 2022-07-21
SA520411638B1 (ar) 2024-03-28
IL273579A (en) 2020-05-31
US10633387B2 (en) 2020-04-28
EP3988552A1 (en) 2022-04-27
PH12020550143A1 (en) 2020-12-07
US11104682B2 (en) 2021-08-31
BR112020006145A2 (pt) 2020-10-20
PL3687996T3 (pl) 2022-02-21
EP3687996B1 (en) 2021-11-03
ECSP20021655A (es) 2020-07-31
AU2023270198A1 (en) 2023-12-14
CY1124952T1 (el) 2023-01-05
CL2020000791A1 (es) 2020-09-25
GEP20227429B (en) 2022-10-25
CO2020005009A2 (es) 2020-05-29
MA50655B1 (fr) 2021-11-30
MX2020003375A (es) 2020-08-03
PE20210002A1 (es) 2021-01-05
HUE057190T2 (hu) 2022-04-28
AU2018342471A1 (en) 2020-04-23
AU2018342471B2 (en) 2023-08-24
JP2020535168A (ja) 2020-12-03
CA3077308A1 (en) 2019-04-04
SI3687996T1 (sl) 2022-04-29
CL2022001014A1 (es) 2022-11-18
JP2024059647A (ja) 2024-05-01
MA50655A (fr) 2021-06-02
MD3687996T2 (ro) 2022-04-30
EP3687996A1 (en) 2020-08-05
TW201920186A (zh) 2019-06-01
SG11202002821UA (en) 2020-04-29
JOP20200081A1 (ar) 2020-04-30
US20200347065A1 (en) 2020-11-05
PT3687996T (pt) 2022-01-21
LT3687996T (lt) 2022-01-10
KR20200088308A (ko) 2020-07-22
CN111386273A (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
EP3797109A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
EP3672973A4 (en) HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
NZ627454A (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
EP3697762A4 (en) AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS, USED AS EHMT2 INHIBITORS, SALTS THEREOF, AND THEIR METHODS OF SYNTHESIS
IL276160A (en) A salt of the compound pyrazolo[5,1-]pyrimidine and its crystals
EA202090384A1 (ru) Промежуточные соединения, используемые для синтеза селективного ингибитора протеинкиназы, и способы их получения
MX2021004918A (es) Derivados de benzodiazepina heterociclica fusionada y usos de estos.
MX2020012718A (es) Derivados de benzodiazepinas novedosos y usos de los mismos.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
PH12020550485A1 (en) Crystalline salts of a b-raf kinase inhibitor
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA202090836A1 (ru) Соли производных пирролотриазинов, пригодных для использования в качестве ингибиторов tam
AR112838A1 (es) Sales de inhibidores de tam